JW (Cayman) Therapeutics Co. Ltd
JW (Cayman) Therapeutics Co. Ltd, a clinical stage cell therapy company, engages in the research and development, manufacture, and marketing of cellular immunotherapy products in the People's Republic of China. The company offers cell-based immunotherapies, including CAR-T treatment, a treatment method that uses human immune cells to fight cancer. Its lead product candidate is Carteyva (relmacabt… Read more
JW (Cayman) Therapeutics Co. Ltd - Asset Resilience Ratio
JW (Cayman) Therapeutics Co. Ltd (JWCTF) has an Asset Resilience Ratio of 0.31% as of December 2024. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2018–2024)
This chart shows how JW (Cayman) Therapeutics Co. Ltd's Asset Resilience Ratio has changed over time. Compare with other companies' asset resilience ratios.
Liquid Assets Composition Over Time
This chart breaks down JW (Cayman) Therapeutics Co. Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $5.16 Million | 0.31% |
| Total Liquid Assets | $5.16 Million | 0.31% |
Asset Resilience Insights
- Limited Liquidity: JW (Cayman) Therapeutics Co. Ltd maintains only 0.31% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
JW (Cayman) Therapeutics Co. Ltd Industry Peers by Asset Resilience Ratio
Compare JW (Cayman) Therapeutics Co. Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Halozyme Therapeutics Inc
NASDAQ:HALO |
Biotechnology | 12.71% |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 3.28% |
|
ESSA Pharma Inc
NASDAQ:EPIX |
Biotechnology | 21.42% |
|
Shenzhen CAU Technology Co Ltd
SHE:000004 |
Biotechnology | 6.20% |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403 |
Biotechnology | 6.88% |
|
Nanhua Bio Medicine Co Ltd
SHE:000504 |
Biotechnology | 11.93% |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518 |
Biotechnology | 0.03% |
|
Chengzhi Shareholding Co Ltd
SHE:000990 |
Biotechnology | 6.73% |
Annual Asset Resilience Ratio for JW (Cayman) Therapeutics Co. Ltd (2018–2024)
The table below shows the annual Asset Resilience Ratio data for JW (Cayman) Therapeutics Co. Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 0.31% | $5.16 Million | $1.68 Billion | +0.05pp |
| 2023-12-31 | 0.26% | $5.53 Million | $2.15 Billion | +0.06pp |
| 2022-12-31 | 0.20% | $5.54 Million | $2.79 Billion | +0.18pp |
| 2021-12-31 | 0.02% | $695.00K | $3.12 Billion | 0.00pp |
| 2020-12-31 | 0.02% | $863.00K | $3.78 Billion | +0.01pp |
| 2019-12-31 | 0.01% | $87.00K | $668.62 Million | -0.08pp |
| 2018-12-31 | 0.10% | $331.00K | $340.82 Million | -- |